Insights

Clinical Stage Innovations Sorrento Therapeutics is a frontrunner in developing innovative therapies for cancer, autoimmune, viral, and neurodegenerative diseases through modalities like CAR-T, ADCs, and oncolytic viruses. This presents a sales opportunity for partnerships or collaborations in advancing these cutting-edge treatments.

COVID-19 Solutions With a range of COVID-19 antiviral therapies, vaccines, and diagnostic tests in development, Sorrento Therapeutics is actively contributing to pandemic response efforts. Sales teams can explore opportunities for distributing or co-marketing these solutions, especially in regions with high demand.

Pain Management Portfolio Sorrento's clinical candidates for pain management, such as RTX and SEMDEXA, offer a unique approach to addressing this market need. Sales professionals can explore partnerships with healthcare providers or pharmacies to introduce these solutions to patients seeking alternative pain treatments.

Rapid Testing Instrument The development of a rapid testing instrument capable of identifying viruses, proteins, and small molecules opens up opportunities for sales in the diagnostics sector. Sales reps can target healthcare facilities, research labs, and government agencies looking to enhance their testing capabilities.

Financial Backing Despite recent legal challenges, Sorrento secured substantial financing, indicating financial stability. This presents a sales opportunity for financial institutions or investment firms to provide additional funding or advisory services to support the company's growth and R&D initiatives.

Similar companies to Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. Tech Stack

Sorrento Therapeutics, Inc. uses 8 technology products and services including SAS/STAT, SOLIDWORKS, WordPress, and more. Explore Sorrento Therapeutics, Inc.'s tech stack below.

  • SAS/STAT
    Advanced Analytics And Data Science
  • SOLIDWORKS
    Cad & Graphics
  • WordPress
    Content Management System
  • Twitter Emoji (Twemoji)
    Font Scripts
  • Modernizr
    Javascript Libraries
  • BambooHR
    Recruitment Marketing
  • Indi
    Referral Marketing
  • Adobe Acrobat DC
    Rich Text Editors

Media & News

Sorrento Therapeutics, Inc.'s Email Address Formats

Sorrento Therapeutics, Inc. uses at least 1 format(s):
Sorrento Therapeutics, Inc. Email FormatsExamplePercentage
FLast@sorrentotherapeutics.comJDoe@sorrentotherapeutics.com
93%
F.Last@sorrentotherapeutics.comJ.Doe@sorrentotherapeutics.com
4%
First.Last@sorrentotherapeutics.comJohn.Doe@sorrentotherapeutics.com
2%
FMiddleLast@sorrentotherapeutics.comJMichaelDoe@sorrentotherapeutics.com
1%

Frequently Asked Questions

Where is Sorrento Therapeutics, Inc.'s headquarters located?

Minus sign iconPlus sign icon
Sorrento Therapeutics, Inc.'s main headquarters is located at 4955 Directors Place San Diego, California 92121 US. The company has employees across 6 continents, including North AmericaEuropeAsia.

What is Sorrento Therapeutics, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Sorrento Therapeutics, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Sorrento Therapeutics, Inc.'s stock symbol?

Minus sign iconPlus sign icon
Sorrento Therapeutics, Inc. is a publicly traded company; the company's stock symbol is SRNE.

What is Sorrento Therapeutics, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Sorrento Therapeutics, Inc.'s official website is sorrentotherapeutics.com and has social profiles on LinkedIn.

How much revenue does Sorrento Therapeutics, Inc. generate?

Minus sign iconPlus sign icon
As of January 2025, Sorrento Therapeutics, Inc.'s annual revenue reached $750M.

What is Sorrento Therapeutics, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Sorrento Therapeutics, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Sorrento Therapeutics, Inc. have currently?

Minus sign iconPlus sign icon
As of January 2025, Sorrento Therapeutics, Inc. has approximately 501 employees across 6 continents, including North AmericaEuropeAsia. Key team members include Chief Executive Officer: H. J.Chief Executive Officer: H. J.CMO: J. Z.. Explore Sorrento Therapeutics, Inc.'s employee directory with LeadIQ.

What industry does Sorrento Therapeutics, Inc. belong to?

Minus sign iconPlus sign icon
Sorrento Therapeutics, Inc. operates in the Biotechnology Research industry.

What technology does Sorrento Therapeutics, Inc. use?

Minus sign iconPlus sign icon
Sorrento Therapeutics, Inc.'s tech stack includes SAS/STATSOLIDWORKSWordPressTwitter Emoji (Twemoji)ModernizrBambooHRIndiAdobe Acrobat DC.

What is Sorrento Therapeutics, Inc.'s email format?

Minus sign iconPlus sign icon
Sorrento Therapeutics, Inc.'s email format typically follows the pattern of . Find more Sorrento Therapeutics, Inc. email formats with LeadIQ.

How much funding has Sorrento Therapeutics, Inc. raised to date?

Minus sign iconPlus sign icon
As of January 2025, Sorrento Therapeutics, Inc. has raised $25M in funding. The last funding round occurred on Oct 09, 2019 for $25M.

When was Sorrento Therapeutics, Inc. founded?

Minus sign iconPlus sign icon
Sorrento Therapeutics, Inc. was founded in 2009.
Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc.

Biotechnology ResearchCalifornia, United States501-1000 Employees

Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical needs. Our vision is to leverage our proprietary G-MAB™ library in conjunction with a proprietary targeted delivery modalities to generate the next generation of therapeutics for treating cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. These modalities include proprietary chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T™), antibody-drug conjugates (ADCs), oncolytic virus (Seprehvec™), lymphatic drug targeting (SOFUSA®), as well as bispecific antibody approaches. We are additionally developing pain management solutions, including our clinical candidates resiniferatoxin (RTX) and SEMDEXA™. In response to the global SARS-CoV-2 (“COVID-19”) pandemic, we are also developing and conducting clinical studies for potential coronavirus antiviral therapies and vaccines, including Abivertinib, COVI-MSC™, COVI-AMG™, COVIDROPS™, and COVI SHIELD™, and diagnostic test solutions, such as COVISTIX™ and COVITRACK™.

Section iconCompany Overview

Headquarters
4955 Directors Place San Diego, California 92121 US
Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
SRNE
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2009
Employees
501-1000

Section iconFunding & Financials

  • $25M

    Sorrento Therapeutics, Inc. has raised a total of $25M of funding over 8 rounds. Their latest funding round was raised on Oct 09, 2019 in the amount of $25M.

  • $100M$1B

    Sorrento Therapeutics, Inc.'s revenue is in the range of $100M$1B

Section iconFunding & Financials

  • $25M

    Sorrento Therapeutics, Inc. has raised a total of $25M of funding over 8 rounds. Their latest funding round was raised on Oct 09, 2019 in the amount of $25M.

  • $100M$1B

    Sorrento Therapeutics, Inc.'s revenue is in the range of $100M$1B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.